Zealand Pharma AS (CHIX:ZEALC) FFO


CHIX:ZEALC Zealand Pharma AS CHIX:ZEALC
58 GF Score
Price kr278.70
GF Value kr12,534.75
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:ZEALC
58GF Score
Zealand Pharma AS CHIX:ZEALC
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (CHIX:ZEALC) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of kr278.70 is trading 97.8% below its estimated GF Value™ of kr12,534.75. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for CHIX:ZEALC:

  • FFO:
  • GF Value™: kr12,534.75 vs. price of kr278.70 (97.8% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the CHIX:ZEALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
58GF Score

Get the complete analysis for CHIX:ZEALC

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr278.70
Price
kr12,534.75
GF Value